olmesartan medoxomil has been researched along with Aortic Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Egashira, K; Hiasa, K; Inoue, S; Ishibashi, M; Kitamoto, S; Ni, W; Nishida, K; Takeshita, A; Usui, M; Zhao, Q | 1 |
1 other study(ies) available for olmesartan medoxomil and Aortic Diseases
| Article | Year |
|---|---|
Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Chemokine CCL2; Chemokines; Cytokines; Disease Progression; Gene Expression Regulation; Gene Targeting; Humans; Hyperlipoproteinemia Type II; Imidazoles; Inflammation; Inflammation Mediators; Injections, Intramuscular; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Olmesartan Medoxomil; Random Allocation; Recombinant Fusion Proteins; Sequence Deletion; Single-Blind Method; Tetrazoles | 2004 |